newsfilter
← Latest News
GlobeNewswire·

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

IMMX
  • The FDA granted Breakthrough Therapy Designation to NXC-201 for treating relapsed/refractory AL Amyloidosis based on positive interim Phase 2 results from the NEXICART-2 trial.
  • Interim clinical data was presented at the American Society of Hematology (ASH) 2025 annual meeting on December 7, 2025.
  • Final trial data is expected this year followed by a planned Biologics License Application (BLA) submission.
  • NXC-201 is the only therapy in active development for relapsed/refractory AL Amyloidosis to receive FDA Breakthrough Designation as no approved therapies currently exist for the condition.
  • The NEXICART-2 trial is an ongoing multi-site U.S. Phase 2 study with a registrational design expected to enroll 40 patients.
  • NXC-201 is a sterically-optimized BCMA-targeted CAR-T cell therapy featuring a "digital filter" designed to eliminate non-specific activation.
  • NXC-201 has also received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, as well as Orphan Drug Designation (ODD) from both the US FDA & the EU EMA.
  • Immix Biopharma estimates the U.S. patient population for relapsed/refractory AL Amyloidosis will reach approximately 38,500 in 2026.
  • The AL Amyloidosis market is projected to grow from $3.6 billion in 2017 to $6 billion in 2025.